Frontlight ResearchEarly access
Not yet taking people in NetherlandsPhase 1/2
Imaging test with a radioactive tracer to find prostate cancer
Tests a radioactive PET scan tracer in men with prostate cancer.
Key facts
- Who runs it
- Radboud universitair medisch centrum Stichting
- Where
- Nijmegen, NetherlandsSee the site
- Trial code
- Registry title
- [89Zr]Zr-PSMA-N139 PET/CT imaging in primary and recurrent prostate cancer.
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 20 people, planned
- Started
- 1 Oct 2026
- Expected to end
- 1 Nov 2027
- Type of study
- Interventional
- Record updated
- 9 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer, either newly diagnosed or returned after earlier treatment. It tests PET/CT imaging with [89Zr]Zr-PSMA-N139.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Prostate adenocarcinoma, newly diagnosed (primary) or recurrent
Where in Netherlands
- Radboud universitair medisch centrum StichtingNijmegen, NetherlandsNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Imaging test with a radioactive tracer to find prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 10 November 2026.
- Record updated
- 9 November 2026